Key Findings
Novartis has announced that delpacibart etedesiran (del-desiran), an antibody-oligonucleotide conjugate (AOC) drug for myotonic dystrophy type 1 (DM1), failed to achieve a statistically significant improvement in its primary endpoint, video hand opening time (vHOT), during the Phase III HARBOR study. This outcome represents a significant setback in the ongoing development of new DM1 therapies.
Technical and Clinical Details
Delpacibart etedesiran was designed as an AOC, combining siRNA (small interfering RNA) technology with an antibody, with the aim of reducing the abnormal mRNA expression of the DMPK gene (myotonic dystrophy protein kinase gene), which is the root cause of DM1. The repeat expansion in the DMPK gene leads to the accumulation of toxic RNA in cells, disrupting the function of various proteins and causing the multi-systemic symptoms of DM1. The HARBOR study was designed to evaluate improvements in motor function in DM1 patients, particularly hand opening and closing ability (vHOT), as its primary endpoint. However, according to Novartis’ announcement, del-desiran did not show a statistically significant improvement in vHOT compared to the placebo arm. This result suggests the need for further research into the efficacy of siRNA approaches and delivery mechanisms for the complex pathophysiology of DM1.
Background & Context
Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults, characterized by progressive muscle weakness, myotonia (delayed muscle relaxation), and multi-organ involvement. It is a severe genetic disorder for which there are currently no approved disease-modifying treatments, leaving a very high unmet medical need. RNA-based therapies, such as siRNAs and ASOs (antisense oligonucleotides), have garnered significant expectations for DM1 treatment due due to their ability to intervene at the genetic level to address the root cause of the disease. Novartis’ Phase III trial failure underscores the complexity and challenges inherent in developing RNA-based therapies for rare diseases.
Strategic Significance & Outlook
The failure of the delpacibart etedesiran Phase III trial is a disappointing outcome for Novartis and the entire DM1 community. This result emphasizes the critical need for further research to deepen the understanding of DM1’s pathomechanisms and to identify more effective targets and delivery methods. Novartis plans to evaluate the full data from this trial to determine its future strategy. Other companies and research groups in DM1 drug development will likely learn from this experience, accelerating the exploration of different approaches, improved RNA therapeutics, or other modalities. A breakthrough remains urgently needed for patients with DM1, a disease with a high unmet medical need.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments